#NephJC #TenPostNephJC.
#NephSky
Video Decision Support and Advance Care Planning in Older Adults with Advanced Kidney Disease
Can a video decision aid help patients with dialysis decisions?
Read the article 👇 VIDEO KD
jamanetwork.com/journals/jam...
#NephJC #TenPostNephJC.
#NephSky
Video Decision Support and Advance Care Planning in Older Adults with Advanced Kidney Disease
Can a video decision aid help patients with dialysis decisions?
Read the article 👇 VIDEO KD
jamanetwork.com/journals/jam...
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#NephJC #TenPostNephJC
Validation of an AI model is difficult. 🤖
Enter the REFINe trial (Reasoning Enhancement With Feedback From a Generative AI in Nephrology), a RCT of large language model (LLM) -assisted diagnostic accuracy in nephrology.
www.kireports.org/article/S246...
#NephJC #TenPostNephJC
Validation of an AI model is difficult. 🤖
Enter the REFINe trial (Reasoning Enhancement With Feedback From a Generative AI in Nephrology), a RCT of large language model (LLM) -assisted diagnostic accuracy in nephrology.
www.kireports.org/article/S246...
The #TenPostNephJC on REACT injections in DKD is live !!
Missed the chat?
Need a short recap of the study ?
We’ve got you covered !! 😃
Welcome to #TenPostNephJC
Can we move beyond slowing CKD → to actually repairing the kidney?
Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.
The #TenPostNephJC on REACT injections in DKD is live !!
Missed the chat?
Need a short recap of the study ?
We’ve got you covered !! 😃
Catch up with the last one tackling adrenal vein sampling. Should you withdraw the MRA and risk rocking the boat, or are you really safe in doing so?
#TenPostNephJC
Last #NephJC we continued our Aldo streak as we discussed mineralocorticoid antagonist (MRA) withdrawal before ✅aldosterone renin ratio (ARR) & adrenal vein sampling (AVS) #NephSky #MedSky
#TenPostNephJC makes this #Endosky oriented topic easy.
pubmed.ncbi.nlm.nih.gov/39660429/
Catch up with the last one tackling adrenal vein sampling. Should you withdraw the MRA and risk rocking the boat, or are you really safe in doing so?
#TenPostNephJC
#NephJC #TenPostNephJC #NephSky
Can just 4 doses of an SGLT2i prevent AKI after cardiac surgery? The MERCURI-2 trial put dapagliflozin to the test. But is the benefit a treat or a trick?🫀💊
Read the article 👇
pubmed.ncbi.nlm.nih.gov/42530910/
#NephJC #TenPostNephJC #NephSky
Can just 4 doses of an SGLT2i prevent AKI after cardiac surgery? The MERCURI-2 trial put dapagliflozin to the test. But is the benefit a treat or a trick?🫀💊
Read the article 👇
pubmed.ncbi.nlm.nih.gov/42530910/
#NephJC #TenPostNephJC
💉Bicarbonate is an ICU drug that almost everyone has an opinion on.
The physiology is attractive, but evidence isn’t.
🥼SODa-BIC asks if IV bicarbonate improves outcomes in ICU pts with metabolic acidosis on vasopressors.
📄 pubmed.ncbi.nlm.nih.gov/42283370/
#NephJC #TenPostNephJC
💉Bicarbonate is an ICU drug that almost everyone has an opinion on.
The physiology is attractive, but evidence isn’t.
🥼SODa-BIC asks if IV bicarbonate improves outcomes in ICU pts with metabolic acidosis on vasopressors.
📄 pubmed.ncbi.nlm.nih.gov/42283370/
FIND-CKD asks: Can we extend nsMRA cardiorenal benefits to the massive population with CKD without diabetes? Let’s FIND out! 🔍
Read the article 👇:
pubmed.ncbi.nlm.nih.gov/42246672/
1/10🧵
FIND-CKD asks: Can we extend nsMRA cardiorenal benefits to the massive population with CKD without diabetes? Let’s FIND out! 🔍
Read the article 👇:
pubmed.ncbi.nlm.nih.gov/42246672/
1/10🧵
#NephSky
1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes?
pubmed.ncbi.nlm.nih.gov/42240165/
#NephSky
1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes?
pubmed.ncbi.nlm.nih.gov/42240165/
MAJESTY hints deeper depletion may do even better
So who earns first line 👀 OBI or rituximab?
Next #NephJC ➡️ Jul 7: TRACK Trial
Join us www.nephjc.com
Great #ERA26, signing off @dramiliflores.bsky.social
#TenPostNephJC #NephTwitter
MAJESTY hints deeper depletion may do even better
So who earns first line 👀 OBI or rituximab?
Next #NephJC ➡️ Jul 7: TRACK Trial
Join us www.nephjc.com
Great #ERA26, signing off @dramiliflores.bsky.social
#TenPostNephJC #NephTwitter
Want more info
Blog by NephJC blog by @jamiekwillows.bsky.social
VA by Divya Bajpai
www.nephjc.com/news/2026/06...
#NephJC #NephSky #TenPostNephJC
Want more info
Blog by NephJC blog by @jamiekwillows.bsky.social
VA by Divya Bajpai
www.nephjc.com/news/2026/06...
#NephJC #NephSky #TenPostNephJC
From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent:
✅ Anti-CD20 therapy works
✅ Remissions are durable
✅ Relapses are lower than CNIs
Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇
#NephJC #TenPostNephJC #NephTwitter #NephSky
From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent:
✅ Anti-CD20 therapy works
✅ Remissions are durable
✅ Relapses are lower than CNIs
Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇
#NephJC #TenPostNephJC #NephTwitter #NephSky
Question
📍 Is obinutuzumab ready to become first-line therapy for pMN?
📍 Would you choose obinutuzumab over rituximab today?
📍 Will improved efficacy justify cost and access challenges?
Tell us what you think 👇
#NephJC #TenPostNephJC#NephSky
Question
📍 Is obinutuzumab ready to become first-line therapy for pMN?
📍 Would you choose obinutuzumab over rituximab today?
📍 Will improved efficacy justify cost and access challenges?
Tell us what you think 👇
#NephJC #TenPostNephJC#NephSky
Not all proteinuria is created equal
Patients receiving TAC were substantially more likely to require rescue immunosuppressive therapy during follow-up.
Remission with OBI was not only more frequent, it was more durable
#NephJC #TenPostNephJC #NephSky
Not all proteinuria is created equal
Patients receiving TAC were substantially more likely to require rescue immunosuppressive therapy during follow-up.
Remission with OBI was not only more frequent, it was more durable
#NephJC #TenPostNephJC #NephSky
A figure paints 🖼️ 1000 words!
At Week 104, complete remission occurred in:
👑 Obinutuzumab ➡️ 37%
📉 Tacrolimus ➡️ 6%
Results were consistent across all subgroups
#NephJC #TenPostNephJC #NephSky
A figure paints 🖼️ 1000 words!
At Week 104, complete remission occurred in:
👑 Obinutuzumab ➡️ 37%
📉 Tacrolimus ➡️ 6%
Results were consistent across all subgroups
#NephJC #TenPostNephJC #NephSky
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
One Post Methods 📚
🎲Phase III, randomized, open-label trial
📍 142 adults with high-risk primary membranous nephropathy
🎯Primary outcome: complete remission at week 104
#NephJC #TenPostNephJC #NephSky
One Post Methods 📚
🎲Phase III, randomized, open-label trial
📍 142 adults with high-risk primary membranous nephropathy
🎯Primary outcome: complete remission at week 104
#NephJC #TenPostNephJC #NephSky
What'd I miss? 👀
📍Obinutuzumab: type II anti-CD20 monoclonal antibody, depletes B cells
📍Tacrolimus: ⬇️ T lymphocytes through FK50-binding protein
📍MAJESTY asks: 👑
Can OBI outperform TAC in durable remission while preserving kidney function?
#ChatGPT #NephJC #TenPostNephJC #NephSky
What'd I miss? 👀
📍Obinutuzumab: type II anti-CD20 monoclonal antibody, depletes B cells
📍Tacrolimus: ⬇️ T lymphocytes through FK50-binding protein
📍MAJESTY asks: 👑
Can OBI outperform TAC in durable remission while preserving kidney function?
#ChatGPT #NephJC #TenPostNephJC #NephSky
With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage
Could deeper B-cell depletion finally claim the throne? 👑
Read the article 👇
pubmed.ncbi.nlm.nih.gov/42246654/
#NephJC #TenPostNephJC #NephSky
With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage
Could deeper B-cell depletion finally claim the throne? 👑
Read the article 👇
pubmed.ncbi.nlm.nih.gov/42246654/
#NephJC #TenPostNephJC #NephSky
#NephSky #NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@glombandit.bsky.social
kidney-international.org/article/S008...
#NephSky #NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@glombandit.bsky.social
kidney-international.org/article/S008...
#NephSky
1/10 Building on the landmark findings of the SBP Intervention Trial, this study shows that team-based HTN care can successfully translate intensive BP control into meaningful CV benefits for underserved, low-income communities.
pubmed.ncbi.nlm.nih.gov/41950472/
#NephSky
1/10 Building on the landmark findings of the SBP Intervention Trial, this study shows that team-based HTN care can successfully translate intensive BP control into meaningful CV benefits for underserved, low-income communities.
pubmed.ncbi.nlm.nih.gov/41950472/
Final call for applications is near ⏳
Fasten your seatbelt… and don’t miss your chance to apply 😉
Until next time @NephJC this was your nephron @dramiliflores.bsky.social ✍️
www.nephjc.com/news/nephjc-...
#TenPostNephJC #NephTwitter #NephSky
Final call for applications is near ⏳
Fasten your seatbelt… and don’t miss your chance to apply 😉
Until next time @NephJC this was your nephron @dramiliflores.bsky.social ✍️
www.nephjc.com/news/nephjc-...
#TenPostNephJC #NephTwitter #NephSky
#TenPostNephJC #NephSky #medsky
➡️ Up next (05/06/26): TRPC6 inhibition in FSGS, a phase 2 trial of BI 764198
pubmed.ncbi.nlm.nih.gov/41616795/
Join us www.nephjc.com
#TenPostNephJC #NephSky #medsky
➡️ Up next (05/06/26): TRPC6 inhibition in FSGS, a phase 2 trial of BI 764198
pubmed.ncbi.nlm.nih.gov/41616795/
Join us www.nephjc.com
Does this study close the gap?
👉 If risk is not increased, does this support hydralazine use?
👉 Why does this debate persist, when in many settings hydralazine use is unnecessary? Why-dralazine?
#TenPostNephJC #NephJC #NephSky #MedSky
Does this study close the gap?
👉 If risk is not increased, does this support hydralazine use?
👉 Why does this debate persist, when in many settings hydralazine use is unnecessary? Why-dralazine?
#TenPostNephJC #NephJC #NephSky #MedSky